Skip to main content
Retour
HROW logo

Harrow Health, Inc.

Qualité des données : 100%
HROW
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
35,20 €
▲ 1,20 € (3,53%)
Cap. Boursière : 1,31B
Fourchette du Jour
33,60 € 35,59 €
Fourchette 52 Semaines
20,85 € 54,85 €
Volume
511 271
Moyenne 50J / 200J
44,58 € / 40,45 €
Clôture Précédente
34,00 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -255,0 0,3
P/B 25,0 2,9
ROE % -8,4 3,7
Net Margin % -1,9 3,8
Rev Growth 5Y % 39,2 10,0
D/E 4,8 0,2

Objectif de Cours des Analystes

Hold
74,25 € +110.9%
Low: 63,00 € High: 94,00 €
P/E Prévisionnel
46,7
BPA Prévisionnel
0,73 €
Croissance BPA (est.)
+0,0%
CA Est.
370 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 8,79 €
8,13 € – 9,96 €
1,1 B 1
FY2029 7,31 €
6,76 € – 8,28 €
970 M 1
FY2028 4,13 €
2,92 € – 5,34 €
740 M 2

Points Clés

Revenue grew 39,22% annually over 5 years — strong growth
Debt/Equity of 4,80 — high leverage
Generating 42,98M in free cash flow
Capital efficient — spends only 0,33% of revenue on capex
Interest coverage of 1,51× — tight debt servicing

Croissance

Revenue Growth (5Y)
39,22%
Revenue (1Y)36,41%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-8,42%
ROIC8,97%
Net Margin-1,89%
Op. Margin13,37%

Sécurité

Debt / Equity
4,80
Current Ratio2,20
Interest Coverage1,51

Valorisation

P/E Ratio
-255,01
P/B Ratio24,99
EV/EBITDA40,92
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 36,41% Revenue Growth (3Y) 44,62%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 39,22% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 272,30M Net Income (TTM) -5,14M
ROE -8,42% ROA -1,29%
Gross Margin 75,05% Operating Margin 13,37%
Net Margin -1,89% Free Cash Flow (TTM) 42,98M
ROIC 8,97% FCF Growth (3Y) N/A
Safety
Debt / Equity 4,80 Current Ratio 2,20
Interest Coverage 1,51 Dividend Yield 0,00%
Valuation
P/E Ratio -255,01 P/B Ratio 24,99
P/S Ratio 4,81 PEG Ratio 4,91
EV/EBITDA 40,92 Dividend Yield 0,00%
Market Cap 1,31B Enterprise Value 1,49B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 272,30M 199,61M 130,19M 88,60M 72,48M
Net Income -5,14M -17,48M -24,41M -14,09M -18,01M
EPS (Diluted) -0,14 -0,49 -0,75 -0,51 -0,69
Gross Profit 204,37M 150,37M 90,55M 63,21M 54,26M
Operating Income 36,40M 8,82M 431 000,0 1,92M 1,61M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 399,48M 388,97M 311,76M 157,38M 98,33M
Total Liabilities 347,39M 319,67M 241,75M 130,14M 87,40M
Shareholders' Equity 52,45M 69,65M 70,36M 27,60M 11,29M
Total Debt 251,98M 228,83M 190,50M 112,23M 77,96M
Cash & Equivalents 72,93M 47,25M 74,09M 96,27M 42,17M
Current Assets 211,75M 189,65M 139,07M 118,26M 60,66M
Current Liabilities 96,30M 91,34M 49,34M 18,63M 9,72M